

Thursday, October 22, 8:00–9:30 a.m. MT

Opening Plenary

**Opening Plenary: ASN President's Address, State-of-the-Art Lecture,
Featured High-Impact Clinical Trials**

Bluebird Ballroom

*Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.
Abstracts in this session will have corresponding poster presentations on the same day in the Exhibit Hall.*

- 9:05 AM **TH-OR109 The ORIGIN 3 Trial: Atacicept in IgA Nephropathy** – Jonathan Barratt, Robert M. Brenner, Sean Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart D. Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimir Tesar, Hernan Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard A. Lafayette
Corresponding Poster ID: TH-PO1257
- 9:12 AM **TH-OR110 Sibeprenlimab in IgA Nephropathy: 24 Months of Data from the Phase 3 VISIONARY Trial** – Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimir Tesar, Hernan Trimarchi, Kevin Carroll, Ian Roberts, Vivekanand Jha, Maria A. Smuclir Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, J. B. Chen, Jose H. Suassuna, Jing Xia, Lokesh N. Shah, Vlado Perkovic
Corresponding Poster ID: TH-PO1258
- 9:19 AM **TH-OR111 Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial** – Jicheng Lv, Lijun Liu, Sydney Tang, Wenxiang Wang, Heather N. Reich, Lin Li, Weihong Mao, Yifan Zhang, Jianmin Fang, Vlado Perkovic, Hong Zhang, TELIGAN Investigators
Corresponding Poster ID: TH-PO1256

Friday, October 23, 10:30 a.m. – 12:30 p.m. MT

Oral Abstract Session

High-Impact Clinical Trials

Bluebird Ballroom

Moderators: Laura M. Dember, MD, FASN; Meg Jardine, MBBS, PhD

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

- 10:30 AM **FR-OR100 ATTACK (Aspirin To Target Arterial events in Chronic Kidney Disease): A Multicentre Randomised Trial of Aspirin vs. Usual Care for the Primary Prevention of Cardiovascular Events in Patients with CKD – Hugh Gallagher, Simon D. Fraser, Sam Wilding, Joshua Northey, Maarten W. Taal, Paul E. Stevens, Robert A. Henderson, Mark Lown, Liz Hartshorne, Jennifer S. Dumbleton, Wendy Daunt, Rosy A. Lampitt, Jonathan N. Townend, Susan Todd, Paul J. Roderick**
- 10:45 AM **FR-OR101 High-Dose Cholecalciferol and Clinical Outcomes in Patients Receiving Dialysis: Results of the SIMPLIFIED Trial – Rona M. Smith, Molly Cui, Fergus Caskey, Afzal Chaudhry, John Cunningham, Toby Humphrey, Sandip Mitra, Inez Schoenmakers, Adam P. Wagner, David C. Wheeler, Ian Wilkinson, Edward C. Wilson, Amer Yahia, Simon Bond, Thomas Hiemstra, on behalf of the SIMPLIFIED Investigators**
- 11:00 AM **FR-OR102 HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy – Zhilian Li, Xueqing Yu, Qiuling Fan, Li Zuo, Deguang Wang, Rong Lv, Junxia Wang, Zhiming Ye, Hui Xu, Leping S. Shao, Yan Yan, Huijuan Mao, Aimin Zhong, Cheng Chen, Wanhong Lu, Lizhi Cao, Louis Brenner, Li Peng, James W. Broderick, Yunna Zang, Yating Wang, Lin Han, Brad Rovin**
- 11:15 AM **FR-OR103 Post-Authorization Efficacy and Safety (PAES): An Open-Label Post-Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe – Oriol Bestard, Amado Andres, Marta Crespo, Fritz Diekmann, Ondrej Viklicky, Dominique Bertrand, Lucrezia Furian, Torbjörn Lundgren, Annelies de Weerd, Rainer Oberbauer, Aiko P. De Vries, Dany Anglicheau, Umberto Maggiore, Fabian Halleck, Miha Arnol, Atul Bagul, Stefan P. Berger, Dirk R. Kuypers, Lutz Renders, Lionel Rostaing, Lina Nilsson, Anna Runström, Jan G. Tollemar, Tomas Lorant**
- 11:30 AM **FR-OR104 Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAGINATION Trial – Jonathan Barratt, Jürgen Floege, Irene L. Noronha, Dana V. Rizk, Hong Zhang, Xiaonong Chen, Dominique Chauveau, Dong Ki Kim, Pedro Augusto M. Souza, Ji (Emmy) Cheng, Vishal Duggal, Nelson Guerreiro, Jeannette Lo, Nadine Schmit, Yixuan Zou, Sean Barbour**
- 11:45 AM **FR-OR105 SWIFT: A Phase 3 Cluster-Randomized Registry Trial of Symptom Monitoring vs. Usual Care in Patients on Hemodialysis – Rachael L. Morton, Chris Brown, Paul N. Bennett, William (Bill) A. Handke, Prerana Nasikkar, Shyamsundar Muthuramalingam, Dana Alhuzaimi, Brendan Smyth, Andrea K. Viecelli, Kathryn Ducharlet, Peter F. Mount, Fergus Caskey, Cécile Couchoud, Stephen P. McDonald, SWIFT Investigators**
- 12:00 PM **FR-OR106 Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis – Shuchi Anand, Glenn M. Chertow, Myles Wolf, Mary O. Dittrich, Gopa Green, Martha Block, Adrian E. Elorriaga, Stephanie Brillhart, Amanda Leppink, F. David Newby, Carolina Arias, Ayodele Erinle, Irfan Agha, Geoffrey A. Block**
- 12:15 PM **FR-OR107 Effects of Ravulizumab on Proteinuria and Hematuria in Patients with IgAN: A Prespecified Interim Analysis of the Phase 3 I CAN Trial – Richard A. Lafayette, Youssef M. Farag, Kara Rice, Tobin J. Cammett, Lesley Inker, Hernan Trimarchi, Annette Bruchfeld, Hiddo J. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Angel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo Infante, Stephen Lake, Ajay K. Singh, Stephen Nolan, Jonathan Barratt, I CAN Study Group**
- 12:30 p.m. Adjourn

Presenting author indicated by underline.



Thursday, October 22, 4:30 p.m. – 6:00 p.m. MT

Oral Abstract Session

Late-Breaking Research Orals: Dialysis and Transplantation

Four Seasons Ballroom 2

Moderators: Nisha Bansal, MD, FASN; Amy K. Mottl, MD, MPH, FASN

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

- 4:30 PM **TH-OR112 Arteriovenous Fistulas, Grafts, or Central Venous Catheters as Vascular Access for Older Adults Starting Hemodialysis: A Randomized Controlled Trial** – Boudewijn Heggen, Koen E. van der Bogt, Friedo W. Dekker, Michiel W. de Haan, Marc H. Hemmelder, Magda V. Loon, Joris I. Rotmans, Geert Willem H. Schurink, Jan Tordoir, Maarten G. Snoeijs, OASIS Study Group
- 4:42 PM **TH-OR113 Randomized Controlled Trial of an Acellular Tissue Engineered Vessel vs. Arteriovenous Fistula for Hemodialysis Access in Female Patients with ESKD: A Phase 3 CLN-PRO-V012 Interim Analysis** – Mohamad A. Hussain, Prabir Roy-Chaudhury, Sophia Bou-Ghannam, Laura E. Niklason, Shamik J. Parikh
- 4:54 PM **TH-OR114 The HOME-BP Trial: Treating Home vs. Predialysis Blood Pressure in Patients on Hemodialysis** – Nisha Bansal, Patrick J. Heagerty, Bryan A. Comstock, Robert Schmicker, Matthew B. Rivara, Jordana B. Cohen, Harini Sarathy, Rajnish Mehrotra, Chi-yuan Hsu
- 5:06 PM **TH-OR115 Efficacy and Safety of the Neokidney Portable Hemodialysis System: Preliminary Phase 1 and 2 Results of the RENEW-HD Trial** – Dian P. Bolhuis, Dieter Bach, Christian Bluechel, Christophe Conan, Maxence Ficheux, Eric Goffin, Joris I. Rotmans, Susan J. Logtenberg, Karin G.F. Gerritsen
- 5:18 PM **TH-OR116 Smart & Fit for Kidney Transplantation (S&F4KTx): A Randomized Controlled 12-Month Trial on the Effects of an Interdisciplinary Prehabilitation Approach in Wait-Listed Patients** – Helge Krusemark, Judith Kleemann, Tobias Hepp, Mario Schiffer
- 5:30 PM **TH-OR117 Pregnancy Outcomes After Living Kidney Donation** – Amit X. Garg, Carol Wang, Kyla L. Naylor, Eric McArthur, James King, Jessica M. Sontrop, Joseph Beyene, Dervla M. Connaughton, Elizabeth M. Hendren, Michelle A. Hladunewich, Ngan Lam, Krista L. Lentine, Rhiannon N. Lyons, Sarah D. McDonald, Pavel Roshanov, Erik Youngson
- 5:42 PM **TH-OR118 Telemedical Management vs. Standard Aftercare Following Kidney Transplantation: The SmartNTx Trial** – Mario Schiffer, Lars Pape, Paul Roll, Roland Roller, Marcel Naik, Fabian Halleck, Oliver Witzke, Klemens Budde
- 06:00 p.m. Adjourn

Friday, October 23, 4:30–6:00 p.m. MT

Oral Abstract Session

Late-Breaking Research Orals: AKI, CKD, CKM, and More

Four Seasons Ballroom 2

Moderators: Tara I. Chang, MD, MS, FASN; Akinlolu Ojo, MD, PhD, MBA, MPH, FASN

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

-
- 4:30 PM **FR-OR108 Acute Treatment of Hyperkalemia in the Emergency Department: A Randomized Clinical Trial** – Emmanuel Montassier, Patrick Rossignol, Matthieu Legrand
- 4:42 PM **FR-OR109 Isuzinaxib Preserves Kidney Function in Patients with CKD Undergoing Percutaneous Coronary Intervention for Contrast-Induced AKI: A Randomized, Double-Blind, Phase 2 Trial** – Hyeon-Cheol Gwon, Dae R. Cha, Sung Hwan Moon, Soo Jin Lee, Hyesung Shin
- 4:54 PM **FR-OR110 CONCORD: A Randomized Controlled Trial of Novel Therapies for Depression in Patients with CKD** – Susan Hedayati, Meredith C. McAdams, Lucile Parker Gregg, Thomas Carmody, Lynnel Goodman, Amelia Dubovsky, Rula A. Abdulrahman, Bethany A. Roehm, Shani Shastri, Xiaoyue Zhang, Katherine R. Tuttle, Madhukar Trivedi, Rajnish Mehrotra
- 5:06 PM **FR-OR111 Effectiveness of Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Protein-Based Vaccine in Individuals with and Without CKD: A Prespecified Analysis of the DAN-RSV Trial** – Katja V. Bartholdy, Mats H. Lassen, Manan Pareek, Niklas Dyrby Johansen, Abby Rudolph, Carmen Rodriguez-Tenreiro Sánchez, Kristoffer G. Skaarup, Brian Claggett, Filip S. Davidovski, Anne B. Nielsen, Lisa Steen Duus, Caroline Espersen, Michael Dalager-Pedersen, Matias G. Lindholm, Lykke Larsen, Lars Kober, Scott D. Solomon, Mónica Conde Pájaro, Cyril J. Martel, Vanessa López Gómez, Iago Giné-Vázquez, Jens Ulrik S. Jensen, Laura Anatale-Tardiff, Federico Martínón-Torres, Tor Biering-Sørensen, FLUNITY-HD Study Group
- 5:18 PM **FR-OR112 Efficacy and Safety of Upacalcet in Patients with Secondary Hyperparathyroidism (SHPT) on Hemodialysis: Two Randomized Controlled Clinical Trials (RCTs)** – Jessica B. Kendrick, Myles Wolf, Biserka H. Tirmenstajn Jankovic, Aaron Camp, Eleanor Copeland, Bastian Dehmel, Geoff Block
- 5:30 PM **FR-OR113 Effects of Low-Dose Rivaroxaban on Cardiovascular Events in Patients with Advanced Kidney Disease According to Baseline Aspirin Use: A Prespecified Subgroup Analysis of the TRACK Trial** – Vivekanand Jha, Vlado Perkovic, Raja Ramachandran, Vinay Rathore, Lily Mushahar, Jan Menne, An S. De Vriese, Patrick Rossignol, Habib Skhiri, Michael Walsh, David T. Collister, Adrian Liew, Laurent Billot, Jeffrey T. Ha, John Eikelboom, Meg Jardine, Muh Geot Wong, Martin P. Gallagher, Sunil Badve, for the TRACK Trial Investigators
- 5:42 PM **FR-OR114 Prognostic Significance of eGFR Change at Week 12 on Kidney Outcomes Associated with Semaglutide Use in the FLOW Trial** – Allon N. Friedman, Katherine R. Tuttle, Kenneth W. Mahaffey, Richard E. Pratley, Peter Rossing, Willem A. Bax, Srikanth Bellary, David M. Charytan, Jose L. Gorritz, Linong Ji, Giuseppe Pugliese, Brian Rayner, Roland E. Schmieder, Trine Wellov Boesgaard, Prachi Priyadarshini, Soren Rasmussen, David Cherney
- 6:00 p.m. Adjourn

Saturday, October 24, 4:30–6:00 p.m. MT

Oral Abstract Session

Late-Breaking Research Orals: Pediatrics, Genetics, and Glomerular Diseases

Four Seasons Ballroom 2

Moderators: Vandana Dua Niyar, MD, FASN; Meghan E. Sise, MD, MS

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

-
- 4:30 PM **SA-OR073 Efficacy and Safety of Obinutuzumab in Adolescents with Active Lupus Nephritis: Primary Results from POSTERITY, a Phase II Global Trial** – Marina Vivarelli, Deborah Levy, Gabriel Vega Cornejo, Maria T. Terreri, Aleksandra Zurowska, Adolfin E. Zuta, Joan Calzada-Hernández, Julien Hogan, Sandra Enciso-Peláez, Agustín Remesal, Louise Oni, Peiqing Yu, Felix Erblang, Olga Mitrofanova, William F. Pendergraft, Patricia B. Lehane
- 4:42 PM **SA-OR074 Empagliflozin Therapy in Patients with Autosomal Dominant Polycystic Kidney Disease: A Feasibility Randomized Controlled Trial** – Stephen L. Seliger, Berenice Y. Gitomer, Zhiying You, Wei Wang, Anna Ostrow, Emily Andrews, Charalett E. Diggs, Diana George, Miranda West, Kristen L. Nowak, Terry J. Watnick, Michel Chonchol
- 4:54 PM **SA-OR075 SGLT2 Inhibitors in Alport Syndrome: A National Multicenter Study (GLIFAS)** – Domenico Santoro, GLIFAS Group
- 5:06 PM **SA-OR076 Povecacept for Treatment of IgA Nephropathy: RAINIER Phase 3 Interim Efficacy and Safety Analysis (IA)** – Richard A. Lafayette, Hong Zhang, Seung Hyeok Han, Yusuke Suzuki, James A. Tumlin, Bobby Chacko, Irene L. Noronha, Arvind Madan, Raphael Duivenvoorden, Jamil R. Azzi, Carla M. Nester, Cassie Dong, Neil Ahluwalia, Jiahua Li, Carmen Bozic, Ogo I. Egbuna, Muh Geot Wong, Jonathan Barratt
- 5:18 PM **SA-OR077 Randomized Controlled Phase 2 Study to Evaluate Iptacopan in Participants with Active ANCA-Associated Vasculitis (AAV): Interim Renal-Focused Results** – Grégory Pugnet, Benjamin Terrier, Christian Löffler, Zhanzheng Zhao, Sebastian J. Magri, Jorge A. Brigante, Fatma Alibaz-Oner, Rachel B. Jones, Min Chen, Rodolfo N. Alvarado, Adrian Schreiber, Anna Bazsó, Albrecht Bettrains, Shilpa Muthusamy, Malika Hanser, Julia Wagner, Swati Ghanshani, Prasanna Kumar Nidamarthy, Imelda Schuhmann, Guido Junge
- 5:30 PM **SA-OR078 Sustained Efficacy and Safety in C3 Glomerulopathy Following 36 Months of Oral Treatment with Iptacopan: Interim Participant Results from the APPEAR-C3G Extension Study** – Carla M. Nester, Richard J. Smith, David Kavanagh, Marina Vivarelli, Giuseppe Remuzzi, Minghui Zhao, Edwin K. Wong, Shiwei Cao, Rubeen K. Israni, Raquel Luna Yolba, Severina Jacinto-Sanders, Jean Grisouard, Andrew S. Bomback
- 5:42 PM **SA-OR079 Interim Results from the Adult IgAN and Primary Membranous Nephropathy (pMN) Cohorts in the Atacicept PIONEER Trial** – Richard A. Lafayette, Jonathan Barratt, Chris Mix, Dana V. Rizk, Brad Rovin, Pamela D. Winterberg, Tao Sheng, James A. Tumlin, Glenn M. Chertow, Christoph Wanner
- 6:00 p.m. Adjourn

Thursday, October 22, 10:00 a.m. – 12:00 p.m. MT

Poster Session

Late-Breaking Research Posters

Exhibit Hall

Note: Full abstracts will be posted on the ASN website on the day of presentation, and on the JASN website on November 10.

- TH-PO1228 Nine Million Candidates, Four in Five Unaware: The CKD Detection Gap Limiting Kidney-Protective GLP-1 Receptor Agonist Therapy in US Adults with Type 2 Diabetes** – Ozioma A. Akahara, Saad Nadeem, Omar A. Ayah, Horacio E. Adrogué, Angelina Edwards
- TH-PO1229 Clinical Decision Support Triggers to Improve CKD Screening and Detection in Primary Care: The ALMA-CKD Pragmatic Cluster Randomized Trial** – Antoine Créon, Jacob Andersson Emad, Stephen Nash, Arvid Thunholm, Marie Evans, Edouard Fu, Sara Lind af Hageby, Arvid Sjölander, Stefan H. Jacobson, Juan J. Carrero, ALMA-CKD Trial Investigators
- TH-PO1230 Effect of a Video Decision Aid and Patient-Created Video Declarations on Advance Care Planning Documentation Among Older Adults with Advanced CKD** – Angelo E. Volandes, Joshua R. Lakin, Yuchiao Chang, Charlotta Lindvall, Lisa M. Quintiliani, Andrew L. Lundquist, Annie Liu, Manjula Kurella Tamura, Mark L. Unruh, Susan P. Wong, Aretha Delight Davis, Cynthia Garde, Lori Henault, Sajeewani Samarakoon, Amresh D. Hanchate, Ernest I. Mandel, Jamie A. Green, Kyla Lawson, Seth Randa, Michael K. Paasche-Orlow
- TH-PO1231 Genetically-Anchored Kidney Aging and Risk of Incident CKD** – Che-yi Chou, Sungkweon Cho, David R. Chang, Hung-Lin Chen, Yu-Ting Lin, Hsiu-Yin Chiang, Chin-Chi Kuo
- TH-PO1232 Occupational Heat, Air Pollution, Physiological Heat Strain, and Kidney and Inflammatory Biomarkers Among Guatemalan Sugarcane Workers** – Bonnie N. Young, Lyndsay Krisher, John L. Adgate, Stephen Brindley, Jaime Butler-Dawson, Laura D. Calvimontes Barrientos, Miranda Dally, Katherine A. James, Kevin Josey, Joshua Schaeffer, Lee S. Newman
- TH-PO1233 Redefining the Natural History and Management of Sickle Cell Kidney Disease (SCKD): Integration of Systematic Evidence with the American Society of Hematology Research Collaborative (ASH RC) Data Hub** – Santosh Saraf, Kirk N. Campbell, Vimal K. Derebail, Jeffrey Lebensburger, Claire C. Sharpe, Kenneth I. Ataga, Julia Seaman, Isabel E. Allen, Alain J. Romero, on behalf of the KHI SCKD Project
- TH-PO1234 Targeted Autosomal Dominant Tubulointerstitial Kidney Disease Gene Evaluation of Early-Onset CKD of Unknown Etiology in Mexico** – J. Emilio Said, Konighinn L. Derflinger Hernández, Alfonso G. Núñez Morales, Norma H. Vázquez, Maria Castañeda-Bueno, Kendrah O. Kidd, Antonio Sanchez, Martina Zivna, Tereza Kmochova, Stanislav Kmoch, Anthony J. Bleyer, Eduardo R. Argaiz, Gerardo Gamba, Anna Greka, Silvana Bazua-Valenti
- TH-PO1235 Strong Independent Association of CKD Progression with Cardiovascular (CV) Events in Patients with Moderate-to-Advanced CKD: Results of the PEAK-CKD Study** – Ziad Massy, Natalia Alencar de Pinho, Jean Tardu, Nathalie Mestdagh, Julien Chollet, Maurice Laville, Nicolas Girerd
- TH-PO1236 Effect of Aprocitenan on Kidney Function in Patients with Hypertension, with or Without CKD** – Markus P. Schlaich, Johannes F. Mann, Martine Clozel, Johann Laurent, Alessandro Maresta, Patrick Rossignol

- TH-PO1237 **Electrolyte, Water, and Blood Pressure Homeostasis with Balcinrenone and Dapagliflozin in Patients with CKD: The DapaBaldi-Leap Trial** – Adriana Marton, Dominik Zarembo, Eric Krause, Norihiko Morisawa, Krister Bamberg, Peter J. Greasley, Tzy Tiing Lim, Roland Veelken, Christian Morath, Manfred Rauh, Hans-Georg Kraetsch, Holger Krause, Jens Titze
- TH-PO1238 **Effects of Retatrutide on Kidney Parameters in Participants with Obesity or Overweight and CKD** – Hiddo J. Heerspink, Fady T. Botros, Karla C Hurt, James P. Smith, Peikun Wu, Ilke Tunali, Lisette Koeneman, Daniël H. van Raalte, Petter Bjornstad
- TH-PO1239 **Effects of Finerenone on Kidney and Cardiovascular Outcomes in Patients with CKD and Type 1 Diabetes: An Analysis from FINE-ONE and FIDELITY** – Hiddo J. Heerspink, Andreas L. Birkenfeld, David Cherney, Helen Colhoun, Per-Henrik Groop, Linong Ji, Janet B. McGill, Peter Rossing, Sylvia E. Rosas, Soo Heon Kwak, Carolina Solis-Herrera, Alfredo E. Farjat, Robert Lawatscheck, Julie Russell, Richard E. Pratley
- TH-PO1240 **Finerenone in Patients with FSGS: A FIND-CKD Analysis** – Hiddo J. Heerspink, Rajiv Agarwal, David Cherney, Carolyn S. Lam, Brendon L. Neuen, Katherine R. Tuttle, Christoph Wanner, Pantelis Sarafidis, Jonathan Barratt, Jürgen Floege, Johannes D. Smeijer, Niels Jongs, Mario Berger, Meike Daniela Brinker, Rania Dayoub, Marina Y. Finkelshtein, Patrick Schloemer, Vlado Perkovic
- TH-PO1241 **TREASURE-CKD: Tirzepatide Mechanism of Action Study on Kidney Structure and Function** – Daniël H. van Raalte, David Cherney, Lisette Koeneman, Fady T. Botros, Denis P. Blondin, Karla C Hurt, Peikun Wu, Ajay Kurani, Petter Bjornstad
- TH-PO1242 **Kidney Outcomes Associated with Tirzepatide vs. GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes and CKD** – Tzu-shan Huang, Ho-Hsiang Chang, Jo-Yen Chao, Wei-Ren Lin, Wei-hung Lin
- TH-PO1243 **The Veterans Affairs Pentoxifylline in Diabetic Kidney Disease (VA PTXRx) Study: Baseline Characteristics** – David J. Leehey, Rajiv Agarwal, Bin Xing, Christina E. Clise, Sankar D. Navaneethan, Kristina M. Utzschneider, Douglas E. Lammie, Yongliang Wei, Linda Polzin, Blake S. Glomb, Kimberly Carlson
- TH-PO1244 **Pentoxifylline for Diabetic Kidney Disease: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis** – Rajiv Agarwal, David J. Leehey, Sankar D. Navaneethan, Kristina M. Utzschneider, Bin Xing, Kimberly Carlson
- TH-PO1245 **Activity of the Novel Anti-Soluble Urokinase Plasminogen Activator Receptor (suPAR) Monoclonal Antibody WAL0921 in People with Diabetic Kidney Disease** – Laura Kooienga, Mohamed A. El-Shahawy, Diego Echeverri, Pablo E. Pergola, Ritesh A. Mathur, Rekha Abichandani, Sreedhar A. Mandayam, Suneel M. Udani
- TH-PO1246 **Vertical Sleeve Gastrectomy Is Associated with Improved Cardiac and Kidney Phenotypes in Youth with Obesity and Type 2 Diabetes** – Phoom Narongkiatikhun, Ye Ji Choi, Kristen Miller, Kristen Nadeau, Thomas H. Inge, Laura Pyle, Petter Bjornstad
- TH-PO1247 **Dietary Potassium Liberalization with Fruits and Vegetables in People with CKD: A Randomized Crossover Clinical Trial** – Navdeep Tangri, Rahele Ziaei, Sepideh Mahboobi, Leila Tavakoli, Ranveer S. Brar, Leah E. Cahill, Robert Balshaw, Sarah McNutt, Andrea Fitzsimmons, Brie Seniuk, Drew Hager, Jay P. Hingwala, Rebecca Mollard, Dylan MacKay
- TH-PO1248 **Reducing Dietary Acid with Fruits and Vegetables vs. Oral Alkali in People with CKD (ReDACKD): A Randomized Controlled Feasibility Trial** – Navdeep Tangri, Sepideh Mahboobi, Rebecca Mollard, Bohdan Luhovyy, Rahele Ziaei, Brie Seniuk, Silvia J. Leon Mantilla, Maria V. Estrella, Leah E. Cahill, David T. Collister, Robert Balshaw, Drew Hager, Jay P. Hingwala, Karthik K. Tennankore, Dylan MacKay



- TH-PO1249 Extended-Release Calcifediol Improves Skeletal Remodeling Balance as Assessed by a CKD-Adapted Bone Balance Index** – Akhtar Ashfaq, John Choe, Kinal Bhatt, Charles W. Bishop, OPKO Renal Division
- TH-PO1250 Telitacicept in Patients with Refractory IgA Nephropathy: A Randomized, Open-Label Clinical Trial** – Shang Liu, Hong Cai, Jiayi Yan, Leyi Gu, Shan Mou, Qin Wang
- TH-PO1251 Sarcopenic Obesity and Gut-Derived Glycylvaline in Relation to Myocardial Fibrosis in Patients with ESRD on Maintenance Dialysis** – Shang Liu, Hong Cai, Youqi Liu, Shan Mou
- TH-PO1252 Long-Term Efficacy and Safety of Iptacopan in Patients with IgA Nephropathy** – Brad Rovin, Hernan Trimarchi, Bart D. Maes, Vlado Perkovic, Naoki Kashihara, Hong Zhang, Jonathan Barratt, Katarina Petrovic-Bulatovic, Zenab Attari, Severina Jacinto-Sanders, Annabel R. Magirr, Ronny Renfurm, Thomas Hach, Dana V. Rizk
- TH-PO1253 Finerenone in Patients with IgA Nephropathy: A FIND-CKD Analysis** – Brendon L. Neuen, Hiddo J. Heerspink, Rajiv Agarwal, David Cherney, Carolyn S. Lam, Katherine R. Tuttle, Christoph Wanner, Pantelis Sarafidis, Yusuke Suzuki, Jonathan Barratt, Jürgen Floege, Niels Jongs, Johannes D. Smeijer, Mario Berger, Aidan MacNamara, Meike Daniela Brinker, Min Chen, Rania Dayoub, Patrick Schloemer, Vlado Perkovic
- TH-PO1254 Efficacy and Safety of B-Cell-Directed Therapies in IgA Nephropathy: A Collaborative Meta-Analysis** – Brendon L. Neuen, Bryony A. Beal, Jonathan Barratt, Robert A. Fletcher, Kirk N. Campbell, Richard A. Lafayette, Hiddo J. Heerspink, Jicheng Lv, Dana V. Rizk, Brad Rovin, Hong Zhang, Vlado Perkovic, CLARITY-IgAN Consortium
- TH-PO1255 A Randomized, Placebo-Controlled Phase 2 Trial of a Long-Acting, C3-Targeting siRNA in IgA Nephropathy** – Jicheng Lv, Jie Chang, Henglan Wu, Rui Yan, Shuang Hou, Guisen Li, Qun Luo, Hualin Qi, Lingling Zhu, Julia Yang, Zhiqiang Du, Haitao Li, Yuanyu Huang, Hong Zhang
- TH-PO1256 Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial** – Jicheng Lv, Lijun Liu, Sydney Tang, Wenxiang Wang, Heather N. Reich, Lin Li, Weihong Mao, Yifan Zhang, Jianmin Fang, Vlado Perkovic, Hong Zhang
Corresponding Oral Abstract ID: TH-OR111
- TH-PO1257 The ORIGIN 3 Trial: Atacicept in IgA Nephropathy** – Jonathan Barratt, Robert M. Brenner, Sean Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart D. Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimir Tesar, Hernan Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard A. Lafayette
Corresponding Oral Abstract ID: TH-OR109
- TH-PO1258 Sibeprenlimab in IgA Nephropathy: 24 Months of Data from the Phase 3 VISIONARY Trial** – Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard A. Lafayette, Vladimir Tesar, Hernan Trimarchi, Kevin Carroll, Ian Roberts, Vivekanand Jha, Maria A. Smuclir Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, J. B. Chen, Jose H. Suassuna, Jing Xia, Lokesh N. Shah, Vlado Perkovic
Corresponding Oral Abstract ID: TH-OR110
- TH-PO1259 Interim Phase 2 Results of SGB-9768, a Liver-Targeted GalNAc-siRNA-Targeting Complement C3, in IgA Nephropathy, C3 Glomerulopathy, and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)** – Minghui Zhao, Hong Zhang, Ying Tan, Jicheng Lv, Guisen Li, Xiaowei Li, Lili Sheng, Yuyan Jin, Dan Duan, Xuekun Yao, Study SGB-9768-003 Investigators

- TH-PO1260 Relationship Between Proteinuria Reduction and Preservation of GFR in Patients with IgA Nephropathy** – Bryony A. Beal, Robert A. Fletcher, Vlado Perkovic, Jonathan Barratt, Chee Kay Cheung, Hiddo J. Heerspink, Meg Jardine, Dana Kim, Jicheng Lv, Heather N. Reich, Dana V. Rizk, Brad Rovin, Muh Geot Wong, Hong Zhang, Brendon L. Neuen
- TH-PO1261 First-in-Human Clinical Trial of CPV-104, a Recombinant Version of Human Complement Factor H: Safety, Tolerability, and Pharmacokinetics for C3 Glomerulopathy** – Michael S. Wiesener, Dinesh Khullar, Bernd Jilma, Peter Zipfel, Martin Bauer, Björn Cochlovius
- TH-PO1262 Efficacy and Safety of Eculizumab in Patients with Anti-Glomerular Basement Membrane Disease: An Investigator-Initiated, Open-Label, Phase 2 Clinical Trial** – Huang Kuang, Xiaoyu Jia, Zhao Cui, Minghui Zhao
- TH-PO1263 Molecular Profiling of Antinephrin Autoantibodies Reveals IgG3/IgG4 Predominance and Shared Immunodominant Epitopes in Recurrent FSGS** – Marie-Camille Lafargue, Ana Flavia Santarine Laureano, Frank E. Hullekes, Rucháma Verhoeff, Christian Leguern, Paolo Cravedi, Leonardo V. Riella, on behalf of the TANGO Consortium
- TH-PO1264 Maintenance Rituximab Reduces Relapse in Phospholipase A2 Receptor (PLA2R)-Related Membranous Nephropathy: A Retrospective Cohort Study** – Jingyuan Xie, Xiaofan Hu
- TH-PO1265 A Phase 2 Open-Label Trial Evaluating the Efficacy and Safety of Daratumumab (Dara) in Treatment of Patients with Active Lupus Nephritis (LN)** – Ladan Zand, Maria J. Vargas-Brochero, Ali Duarte-Garcia, Fernando C. Fervenza
- TH-PO1266 Cross-Ancestry Transferability of a Tubulointerstitial Molecular Classification to an Indigenous West African Cohort with Proteinuric Disease** – Maame Esi B. Annor-Apafo, Felix H. Eichinger, Gabor Halasz, Viji Nair, Mathew O. Alaba, Min Ni, Brad A. Godfrey, Wanda Sharif-Rodriguez, Mary E. Haas, Lori Morton, Kishor B. Devalaraja-Narashimha, Jeffrey B. Hodgin, Matthias Kretzler, Dwomoa Adu, Akinlolu Ojo
- TH-PO1267** Withdrawn
- TH-PO1268 GLP-1 Receptor Agonist Therapy Within Three Years After Kidney Transplant Is Associated with Improved Graft and Patient Survival** – Sakib Salam, Winn T. Cashion, Duo Yu, Siavash Raigani
- TH-PO1269 Early Experience of Sibeprenlimab in Kidney Transplant Recipients with Disease Recurrence and Antibody Mediated Rejection** – Yasir A. Qazi
- TH-PO1270 Biopsy-Guided Management Improves Renal Outcomes After Liver Transplantation: A Matched Cohort Study** – Xiaoyan Liu, Anxiang Cai, Haijiao Jin, Yize Bian, Qin Wang, Yongbing Qian, Jiang Zhang, Yao Xu, Wenyan Zhou, Chaojun Qi, Minfang Zhang, Jianjun Zhang, Shan Mou
- TH-PO1271 The ODYSSEE-Kidney Health Trial for Home Kidney Replacement Therapy (KRT)** – Christopher T. Chan, Robert Nolan, on behalf of the ODYSSEE-Kidney Health Team
- TH-PO1272 Use of the CloudCath Remote Monitoring System Is Associated with Retention on Peritoneal Dialysis** – Don E. Williamson, Eric H. Yu, Leon Rovner, Jeffrey L. Hymes, Glenn M. Chertow
- TH-PO1273 Niaoduqing Granules Improve Constipation in Patients with Peritoneal Dialysis: A Multicenter Prospective Controlled Study** – Miao Li, Huiping Zhao, Bin Zhao, Lingju Yue, Jiaxiang Ding, Wei Zhao, Xuejiao Liu, Gang Fu, Zhongxin Li, Feng Yu, Haidan Zhao, Jianfang Cai, Li Zuo

- TH-PO1274 ACTIVE-PD: Supervised Physical Exercise Improves Maximal Oxygen Consumption (VO₂max) and Physical Function in Patients on Automated Peritoneal Dialysis** – Yadira Mariaca Ortiz, Christopher Barrera-Hoffmann, Gabriela M. Peña Delgado, Andrea L. Arrieta Damian, Gabriela Leal Escobar, Luis D. Ramirez-Calvillo, Karla B. Cano Escobar
- TH-PO1275 MotiVational Strategies to Empower African Americans to Improve Dialysis Adherence (MoVE Trial): A Randomized Controlled Trial** – Jeshanah Johnson, Ruth Q. Wolever, Marylou Ejezie, Heather L. Prigmore, Daniel C. Niter, Julianna Forbess, Anita Medepalli, Lesa R. Abney, Shena Gazaway, Devika Nair, Rachel B. Burdick, Julia Lewis, Kerri L. Cavanaugh, Robert Greevy, Kenneth A. Resnicow, Sarah J. Schrauben, Ebele M. Umeukeje
- TH-PO1276 GLP-1 Receptor Agonist Initiation and Mortality in Patients on Maintenance Hemodialysis: A Target Trial Emulation** – Suman K. Lama, Sheetal Chaudhuri, Derek M. Blankenship, Andrea Nandorine Ban, Len A. Usvyat, Roberto Pecoits-Filho, Benjamin E. Hippen
- TH-PO1277 Efficacy and Safety of Gosicalcetide vs. Cinacalcet in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis: Results from a Phase 3 Randomized Clinical Trial** – Xueqing Yu, Zhiming Ye, Sijia Li, Renwei Huang, Li Fan, Jing Yang, Aiyong Liu, Ming Yang, Wenxiu Chang, Shuxin Liu, Xin Zhang, Xue Yang, Lili Pan
- TH-PO1278 Long-Term Safety of Gosicalcetide in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis** – Li Zuo, Liangying Gan, Guangyu Bi, Bi hu Gao, Ying Zeng, Hong Ye, Aiyong Liu, Xiaowei Li, Yuan Qin, Zhijian Zhang, Yun Jin, Xue Yang, Lili Pan
- TH-PO1279 Sodium Thiosulfate Attenuates Coronary Artery Calcification and Uremic Pruritus: A Randomized Crossover Trial** – Chensi Sun, Jiao J. Hao, Hongli Lin
- TH-PO1280 Effect of Intradialytic Exercise on Serum Fibroblast Growth Factor 23 (FGF-23) Levels and Left Ventricular Structure and Function in Patients on Hemodialysis: A Randomized Controlled Trial Pilot Study** – Seuppong Naka, Suree Yoowannakul
- TH-PO1281 Spectrum and Burden of Arrhythmias in Patients with ESKD on Maintenance Hemodialysis: A 48-Hour Holter Monitoring Study** – Barundeep Singh, M. P. S. Chawla, Bharat S. Sambyal, Prabhat Chauhan, Chrisinder Kaur, Ananthakrishnan Ramamoorthy
- TH-PO1282 Outcomes for Veterans in Veterans Affairs (VA) and VA Community Care Dialysis Settings Favor VA and Were Not Impacted by the COVID-19 Pandemic** – Virginia Wang, Cynthia Coffman, Lan Jiang, Kaitlyn B. Goodwin, Matthew L. Maciejewski, Ann M. O'Hare, Clarissa J. Diamantidis, Amal Trivedi
- TH-PO1283 Flow Surveillance or Clinical Monitoring to Guide Vascular Access Maintenance: A Double-Blind Randomized Controlled Trial** – Bianca Zomer, Ellen Goertz, Michiel W. de Haan, Marc H. Hemmelder, Mickaël Hiligsmann, Magda V. Loon, Joris I. Rotmans, Geert Willem H. Schurink, Joost van der Vorst, Maarten G. Snoeijs, FLOW Study Group
- TH-PO1284 Ultrasound-Guided Percutaneous Arteriovenous Fistula Creation (pAVF) in a 1,000-Patient Cohort: Maturation, Patency, and Predictors of Abandonment** – Rashid Sharaf, Jemma Reinhardt, Timoteo Cabrera, Jeffrey E. Hull
- TH-PO1285 Proton Pump Inhibitor Use Is Associated with Improved Arteriovenous Fistula Patency in Patients with ESKD: A Retrospective Cohort Study with Experimental Support** – Yuchi Tu, Lijun Yao
- TH-PO1286 Real-World Effectiveness of Taurolidine/Heparin Catheter Lock Solution in Patients on Hemodialysis with Central Venous Catheters** – Gopa Green, Glenn M. Chertow, Mary O. Dittrich, Martha Block, Stephanie Brillhart, Geoffrey A. Block



- TH-PO1287 **A Decellularized Biological Vascular Graft for Hemodialysis Access: 18-Month First-in-Human Clinical Outcomes of LineMatrix** – Qiu Xuefeng, Ying Guo, Hong Ye, Yuan Luo, Shuangshuang Chen, Hua Li
- TH-PO1288 **Clinical Evaluation of a Novel Polyethersulfone Hemodiafiltration Filter: A Multicenter Randomized Crossover Noninferiority Trial** – Fanna Liu, Ying Tang, Liangmei Chen, Jianwei Yang
- TH-PO1289 **Multihospital Electronic Decision Support for Drug-Associated AKI (MEnD-AKI): A Prospective Cluster-Randomized Clinical Trial** – Sandra Kane-Gill, Christina L. Kazarov, Caiden Lukan, Britney A. Crouse, Jason N. Kennedy, Tezcan Ozrazgat-Baslanti, Esra Adiyek, Raghavan Murugan, Chung-Chou H. Chang, Azra Bihorac, John A. Kellum, MEnD-AKI Study Team
- TH-PO1290 **Early Medication-Specific Recommendations for AKI from the KAT-AKI Trial** – Abinet M. Aklilu, Jayashimman Vasanthraman, Kristina Shvets, Charles Jones, Steven Menez, Yu Yamamoto, Kyle D. O'Connor, Chirag R. Parikh, Francis P. Wilson, Clinical and Translational Research Accelerator (CTRA)
- TH-PO1291 **Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort** – Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung
- TH-PO1292 **eGFR Difference and Platinum-Associated Adverse Events in Patients with Cancer** – Jiaxuan Lyu, Si Yuan Khor, Tianqi Ouyang, Sherley M. Mejia, Katherine C. Specht, Daiana R. Moreno, Harish Shanthanu Seethapathy, Paul Hanna, Leyre Zubiri Oteiza, Kavita Mistry, Nurit S. Katz, Matthew Lei, Jennifer S. Temel, Florian J. Fintelmann, Sachin J. Shah, Lesley Inker, Meghan E. Sise
- TH-PO1293 **Reducing Fluid Overload in Cardiorenal Syndrome by Enhancing Insensible Fluid Loss: The REFORM-HF Trial** – Tuvia Ben Gal, Doron Aronson, Benjamin Stoner, Tamas Alexy, Kunjan Bhatt, Liviu Klein, William Abraham, Scott Feitell
- TH-PO1294 **Can Inferior Vena Cava Diameter and Collapsibility Index Predict Renal Response to Diuretic Therapy in Heart Failure?** – Muammer Avci, Özgür T. Kutlu
- TH-PO1295 **Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models** – Rui Liu, Ophelia Chen, Zhongli Xu, Wantanee Phuapradit, Yazhong Pei, Maria Habel, Renfeng Guo
- TH-PO1296 **First-in-Human Study of SK-09, a Novel Transient Receptor Potential iChannel-5 Inhibitor: Safety, Tolerability, and Pharmacokinetics in Healthy Participants** – Du Ying, Gloria Yee Man Wong
- TH-PO1297 **A Wearable, Real-Time Creatinine Monitor Supports the Early Detection and Quantification of Changing Renal Function** – Robert C. Mcleay, Adele Barnard, Kevin W. Plaxco, Julian Gerson
- TH-PO1298 **Digital Cognitive Behavioral Therapy for Hyperkalemia in Patients on Maintenance Hemodialysis: A Prospective, Single-Center, Randomized Controlled Trial** – Hongli Lin, Xin Zeng